New combo therapy targets tough leukemia in older patients
NCT ID NCT05749276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The study will also look at how well the leukemia responds to treatment. Only 12 participants will be enrolled, and the results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Daratumumab (Darzalex) combined with chemotherapy (idarubicin and cytarabine or CPX-351)
- What this could lead to
- If successful, this could point toward a new treatment option for older adults with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a very early, small phase 1 trial with only 12 participants, focused on safety. It may not lead to an effective treatment, and combining daratumumab with strong chemotherapy carries risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>= 60 ans * Poor prognosis AML defined according to the following criteria:1. For first-line AML:intermediate or unfavorable risk according to ELN 2022 2.for Relapsed AML:regardless of the ELN risk group * ECOG \<= 2 * Patient eligible for intensive chemotherapy * Who provide their written informed consent * Liver workup: transaminases \< 3x normal, bilirubin \< 1.5 X normal * Creatinine clearance \> 60ml/mn * LVEF \>= 50%. Exclusion Criteria: * Patients with FLT3 ITD or TKD mutation * Patients with tuberculosis * Patients with documented active infection with COVID 19 * Patients with hereditary fructose intolerance (HFI) * Uncontrolled infection * Active or past infection with Hep B, C or HIV+ * Not Affiliated with French social security system or no beneficiary from such system * Pregnant women or patients who cannot take contraception ( contraceptive pill, abstinence, unauthorised IUD) in case of fertility. A patient who cannot continue contraception for at least 6 months after the last injection of DARATUMUMAB is not eligible for inclusion. * Breastfeeding women * Minors * Adults under guardianship, curatorship or safeguard of justice * Hypersensitivity to any of the active ingredients or excipients * Patients with significant cardiovascular pathology including any of the following: myocardial infarction within 6 months prior to study entry, unstabilized coronary artery disease, uncontrolled hypertension, congestive heart failure. * Patient with disease requiring systemic immunosuppressive therapy (such as high-dose steroids defined as ≥ 10mg prednisone or equivalent per day) within 4 weeks prior to the 1st scheduled dose of study treatment with the exception of dermocorticoids
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adult patients with adverse risk acute myeloblastic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Nantes
RECRUITINGNantes, 44093, France